Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
itMSCs + itNSCs is a combination cell therapy being developed by Stemedica Cell Technologies. It consists of two allogeneic stem cell products: ischemia-tolerant mesenchymal stem cells (itMSCs) and ischemia-tolerant neural stem cells (itNSCs). These cells are manufactured under proprietary low-oxygen (hypoxic) conditions, which enhances their survival and secretion of growth factors in the ischemic environments typical of stroke and other neurological injuries. The therapy utilizes a dual administration approach: itMSCs are delivered intravenously to promote vascularization and immunomodulation, while itNSCs are delivered intrathecally to migrate to damaged areas, replace lost neurons, and restore neural connectivity. The combination is primarily targeted at chronic ischemic stroke and Alzheimer's disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on itMSCs + itNSCs.